Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

@article{Wilkinson2006EpoetinAI,
  title={Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial},
  author={Peter M. Wilkinson and Minas J. Antonopoulos and Manfred Lahousen and Michael J. Lind and Paris A. Kosmidis},
  journal={British Journal of Cancer},
  year={2006},
  volume={94},
  pages={947 - 954}
}
This multicentre, open-label, controlled clinical trial assessed the effects of epoetin alfa treatment on haematologic and quality of life (QOL) parameters in 182 anaemic (Hb⩽12 g dl−1) ovarian cancer patients receiving platinum chemotherapy. Patients were randomised 2 : 1 to receive epoetin alfa 10 000–20 000 IU three times weekly plus best standard treatment (BST) or BST only. Main study end points were changes from baseline in haemoglobin (Hb) level, transfusion requirements, and QOL. For… CONTINUE READING
18 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

patients receiving epoetin alfa therapy

  • F Dammacco, G Castoldi, S Rödjer
  • 2001
Highly Influential
4 Excerpts

Early intervention with epoetin alfa in breast caner (BC) patients (pts) undergoing chemotherapy (CT): results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group)

  • P Pronzato, E Cortesi, +5 authors R Rosso
  • Ann Oncol
  • 2002
Highly Influential
2 Excerpts

requirements , risks , and costs for patients with malignancy

  • P Pronzato, E Cortesi, +5 authors R Rosso
  • Transfusion
  • 2002
Highly Influential
2 Excerpts

Similar Papers

Loading similar papers…